Jennifer Lorenzini/Reuters   The U.S Food and Drug Administration (FDA) approves Paxlovid for the treatment of mild-to-moderate COVID-19. In a press release On May 25, 2023, the FDA granted Pfizer approval for its antiviral medication for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including […]

  Paxlovid reduces risk of severe COVID-19 in patients with chronic health condition a new study finds. The study which was conducted by researchers at Harvard University was published in June 2023 in the Clinical Infectious Diseases Journal. This investigation will contribute to proper use of the antiviral medication in the treatment of patients in […]

  Paxlovid is an oral antiviral medication for the treatment of COVID-19. It was developed by Pfizer for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, including hospitalization and death. The Food and Drug Administration (FDA) first made Paxlovid available in December 2021 under emergency use authorization for high-risk individuals […]

  Professor Tomas Hanke of the Jenner Institute led Clinical trial shows encouraging results. The trial was conducted across four sites in Kenya, Uganda, and Zambia, and ran from August 2021 to November 2022. It aimed to assess the safety and efficacy of the HIV vaccine candidate.   This study was important because there is […]